Human epidermal growth factor receptor-2 (HER2+) breast cancers compose approximately 15% of all breast cancers and are more likely to be diagnosed in younger patients and at a more advanced stage than the more common hormone receptor-positive, HER2-negative breast cancers [1]. Here, ERBB2 is linked to breast carcinoma.